Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥37.78 Million ≈ $5.53 Million USD) by net assets (CN¥1.05 Billion ≈ $153.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Zhuhai Rundu Pharmaceutical Co Ltd Class for the company's overall valuation and market capitalisation.
Zhuhai Rundu Pharmaceutical Co Ltd Class A - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Zhuhai Rundu Pharmaceutical Co Ltd Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zhuhai Rundu Pharmaceutical Co Ltd Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhuhai Rundu Pharmaceutical Co Ltd Class A ranked by their cash flow conversion efficiency. Explore Zhuhai Rundu Pharmaceutical Co Ltd Class (002923) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sella Real Estate
TA:SLARL
|
0.021x |
|
Bank Maspion Indonesia PT
JK:BMAS
|
0.015x |
|
ZimVie Inc
NASDAQ:ZIMV
|
0.008x |
|
Esso S.A.F.
PA:ES
|
-0.040x |
|
Chenming Mold Industrial Corp
TW:3013
|
0.120x |
|
Rural Funds Group
AU:RFF
|
0.011x |
|
Hangzhou Dadi Haiyang Environmental Protection Co. Ltd.
SHE:301068
|
N/A |
|
Smartoptics Group AS
OL:SMOP
|
0.323x |
Annual Cash Flow Conversion Efficiency for Zhuhai Rundu Pharmaceutical Co Ltd Class A (2011–2025)
The table below shows the annual cash flow conversion efficiency of Zhuhai Rundu Pharmaceutical Co Ltd Class A from 2011 to 2025. View latest Zhuhai Rundu Pharmaceutical Co Ltd Class stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.04 Billion ≈ $151.95 Million |
CN¥104.41 Million ≈ $15.28 Million |
0.101x | -45.15% |
| 2024-12-31 | CN¥1.15 Billion ≈ $168.59 Million |
CN¥211.19 Million ≈ $30.90 Million |
0.183x | +25.17% |
| 2023-12-31 | CN¥1.18 Billion ≈ $172.55 Million |
CN¥172.68 Million ≈ $25.27 Million |
0.146x | +29.73% |
| 2022-12-31 | CN¥1.20 Billion ≈ $175.01 Million |
CN¥135.01 Million ≈ $19.76 Million |
0.113x | -39.03% |
| 2021-12-31 | CN¥1.11 Billion ≈ $162.74 Million |
CN¥205.91 Million ≈ $30.13 Million |
0.185x | -23.22% |
| 2020-12-31 | CN¥1.04 Billion ≈ $151.93 Million |
CN¥250.35 Million ≈ $36.63 Million |
0.241x | +49.86% |
| 2019-12-31 | CN¥940.29 Million ≈ $137.59 Million |
CN¥151.30 Million ≈ $22.14 Million |
0.161x | -11.85% |
| 2018-12-31 | CN¥871.29 Million ≈ $127.50 Million |
CN¥159.04 Million ≈ $23.27 Million |
0.183x | +53.97% |
| 2017-12-31 | CN¥488.84 Million ≈ $71.53 Million |
CN¥57.95 Million ≈ $8.48 Million |
0.119x | -49.82% |
| 2016-12-31 | CN¥398.19 Million ≈ $58.27 Million |
CN¥94.07 Million ≈ $13.77 Million |
0.236x | +46.41% |
| 2015-12-31 | CN¥310.72 Million ≈ $45.47 Million |
CN¥50.14 Million ≈ $7.34 Million |
0.161x | -23.98% |
| 2014-12-31 | CN¥273.31 Million ≈ $39.99 Million |
CN¥58.01 Million ≈ $8.49 Million |
0.212x | +58.34% |
| 2013-12-31 | CN¥236.29 Million ≈ $34.58 Million |
CN¥31.67 Million ≈ $4.63 Million |
0.134x | -61.82% |
| 2012-12-31 | CN¥199.43 Million ≈ $29.18 Million |
CN¥70.01 Million ≈ $10.25 Million |
0.351x | +72.18% |
| 2011-12-31 | CN¥165.33 Million ≈ $24.19 Million |
CN¥33.71 Million ≈ $4.93 Million |
0.204x | -- |
About Zhuhai Rundu Pharmaceutical Co Ltd Class A
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular, gastrointestinal, antibiotics, analgetic and antipyretics, anti-virus, endocrinology, and respiratory; and pellets for excipient, antiulcerative, diabetes … Read more